This company is no longer in business. Investors can get details about any potential exits or failures here.



Early Stage

Lipids for treatment of inflammatory skin diseases, cosmetic and pharmaceutical products based on solid science.

Lipids for treatment of inflammatory skin diseases, cosmetic and pharmaceutical products based on solid science.


Raised this Round: Raised: $2,095

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Healthcare & Pharmaceuticals

Tech Sector


Corvallis, Oregon

Lipidomics, Inc. is here with the solution for inflammatory skin diseases. They develop cosmetics and pharmaceutical products for dry and sensitive skin that help replenish liquids that are deficient in the skin barrier. Lipidomics scientific founders have been studying fundamental skin biology and dermatology for over two decades, and their studies have led them to create a topical application of two specific lipids that are effective for treating dry skin that can often be a precursor to eczema. Current treatments can suppress the immune response or have detrimental effects on skin health. Lipidomics’ product helps prevent that, allowing the integrity of the skin barrier to remain intact without triggering an immune response.
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Lipidomics on Netcapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $2,801,443
Price per Share: $1.94

Follow company

Follow Lipidomics on Netcapital

Buy Lipidomics's Deal Report

Warning: according to the close date for this deal, Lipidomics may no longer be accepting investments.

Lipidomics Deal Report

Get KingsCrowd’s comprehensive report on Lipidomics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Lipidomics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Lipidomics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge